October 2020

The recent focus on disparities in health care comes through in the call to action.

Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted this comparison study of patients with heart failure enrolled in Medicare fee-for-service plans (FFS) and MA plans.

Below are selected abstracts presented at the European Society of Cardiology 2020 Congress, which was held in a virtual format due to the coronavirus disease 2019 pandemic.

A new analysis from the REDUCE-IT trial finds that cardiovascular benefits of Vascepa are consistent no matter what type of statin a patient takes for cholesterol.

The American College of Cardiology updates guidance on prescribing SGLT2 inhibitors and GLP-1 receptor agonists to patients with type 2 diabetes and cardiovascular disease or CV risk.

Results from an analysis conducted by the Pharmacy Benefit Management Institute (PBMI) show that the use of Jardiance (empagliflozin) among employees with type 2 diabetes and cardiovascular disease can save employers around $737,000 per 10,000 covered lives each year.

Researchers constructed a risk prediction model of hospitalizations due to heart failure (HHF) for patients with type 2 diabetes mellitus (T2DM), according to a Clinical Cardiology study.